CYTO Consulting brings Europe's viral vector competence to USA

SIRION Biotech as Europe's Leading Commercial Provider of Viral Vector Technology Opens Massachusetts Office in Cambridge, MA

The SIRION and CYTO teams and speakers ahead of the opening event in Cambridge (PresseBox) ( Lexington, )
Cambridge based CYTO Consulting (“CYTO”) has helped SIRION Biotech GmbH (“SIRION”) opening its second foreign site outside Germany in Cambridge, MA. SIRION is offering the most comprehensive portfolio of custom viral vectors for preclinical and clinical studies in gene therapy. A grand opening event, hosted at the Forsyth Institute in Cambridge MA, was an informal meet-and-greet featuring short presentations from Erik Richardson of Acucela, Dirk Grimm of the University of Heidelberg and Christian Thirion, CEO of Sirion Biotech.

CYTO assists international life sciences companies as they expand into the US market. CYTO offers a full breadth of services from scientific and business services to subsidiary formation.

Establishing a local US presence has been a key strategic objective for SIRION, in order to serve our local customers better than we could from Munich. CYTO Consulting acts as our local partner as it understands our science, the specifics of the US market and it has a well-established local network; this was instrumental in getting things started. CYTO Consulting provided all aspects of our US market entry, including business and tactical planning, US-corporate structure advice, setting up a local office, launch event organization, business development and customer outreach, and even local recruitment.” said Chief Operating Officer and Executive Director of SIRION, Dieter Lingelbach.

“Having CYTO as a reliable partner who can implement our strategy locally was important for the success and speedy execution of our US expansion plan,” added Dr. Christian Thirion, Chief Executive Officer of Sirion.

“Speaking the same language as our clients, certainly helped to transport SIRION’s unique culture from its headquarter in Munich, Germany, into its newly launched US subsidiary in Cambridge, MA,” mentioned Mike Steyer, Senior Partner at CYTO, and SIRION Project Lead.

“SIRION is a key client for CYTO and will be taking advantage of the full breadth of our services. With our hands-on approach, we have been able to get them up to speed quickly and establish their US market presence, thus lowering the risk of a complex endeavor. We are thrilled to have the opportunity to work with such a talented team and exciting technology,” said Dr. Odilo Mueller, President of CYTO.

About SIRION Biotech GmbH

SIRION Biotech provides custom engineering and manufacturing services of viral vectors for the life sciences industry. Its unique focus on improving transduction efficiencies and safety make SIRION Biotech a valuable technology partner for gene and cell therapy trials. LentiBOOSTTM transduction reagent is actively used to improve hematopoitec cell transductions in clinical trials. NextGen AAV capsid evolution projects aim to improve tissue targeting and immune escape of capsids to usher in a new generation of therapeutics for international gene therapy companies.

About CYTO Consulting, LLC

CYTO Consulting's experienced team of scientific and business executives offers hands-on help to international life sciences companies seeking to enter the US market. Focused on assisting international life sciences companies planning to start operations in the US access the world's largest research, pharmaceutical and diagnostics market, CYTO helps refine ideas, develop a strategy and execute plans in the Capital of Innovation. Specializing in the Pharma, analytical instrument, medical device, biotech, and the CRO space, CYTO assists clients enter the US market with a running start.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an